Arthralgias and Myalgias Related to Quinupristin-Dalfopristin Administration
Open Access
- 15 February 2001
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 32 (4) , e83-e86
- https://doi.org/10.1086/318702
Abstract
This study evaluated the frequency of and potential risk factors for arthralgias and/or myalgias associated with quinupristin-dalfopristin administration. Of 32 patients who received quinupristin-dalfopristin treatment, at least 15 (47%) developed arthralgias and/or myalgias. Clinicians should be aware of these adverse events associated with quinupristin-dalfopristin, which may occur more frequently than has been previously reported.Keywords
This publication has 6 references indexed in Scilit:
- Quinupristin/dalfopristin: therapeutic potential for vancomycin-resistant enterococcal infectionsJournal of Antimicrobial Chemotherapy, 1999
- Safety and tolerability of quinupristin/dalfopristin: administration guidelinesJournal of Antimicrobial Chemotherapy, 1999
- Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycinJournal of Antimicrobial Chemotherapy, 1999
- The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faeciumJournal of Antimicrobial Chemotherapy, 1999
- Prospective, Randomized Dose-Ranging Open Phase II Pilot Study of Quinupristin/Dalfopristin versus Vancomycin in the Treatment of Catheter-Related Staphylococcal BacteremiaEuropean Journal of Clinical Microbiology & Infectious Diseases, 1999
- Vancomycin-resistant enterococciPublished by Elsevier ,1997